The data were from the Phase 2 clinical study of high-dose IBI302 (NCT05403749) to evaluate the efficacy, safety and dosing intervals in patients with nAMD over a one-year treatment period. A total of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback